Clinical Cancer Research

A new three-drug “RAD” regimen produced encouraging responses in patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). The early-stage clinical results support further evaluation of this targeted therapy and immunotherapy combination.

Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another kind of drug can overcome this adverse effect, however.